Press coverage about Heron Therapeutics (NASDAQ:HRTX) has trended somewhat positive on Monday, according to Accern Sentiment. The research group ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Heron Therapeutics earned a daily sentiment score of 0.18 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.6912978201998 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.
These are some of the media headlines that may have impacted Accern Sentiment Analysis’s analysis:
- Zacks: Brokerages Anticipate Heron Therapeutics Inc (HRTX) Will Announce Quarterly Sales of $10.92 Million (americanbankingnews.com)
- Heron Therapeutics Inc (HRTX) Given Consensus Rating of “Buy” by Brokerages (americanbankingnews.com)
- -$0.85 EPS Expected for Heron Therapeutics Inc (HRTX) This Quarter (americanbankingnews.com)
- Contrasting Heron Therapeutics (HRTX) and Arsanis (ASNS) (americanbankingnews.com)
- Keep an eye on Analysts Rating: Heron Therapeutics, Inc. (HRTX) – Wall Street Morning (wallstreetmorning.com)
Several analysts recently weighed in on the company. ValuEngine downgraded Heron Therapeutics from a “hold” rating to a “sell” rating in a report on Wednesday, March 7th. Noble Financial restated a “buy” rating on shares of Heron Therapeutics in a report on Friday, March 2nd. Oppenheimer set a $27.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a report on Thursday, March 1st. Needham & Company LLC restated a “buy” rating and issued a $30.00 price objective (up from $28.00) on shares of Heron Therapeutics in a report on Thursday, March 1st. Finally, Cantor Fitzgerald set a $31.00 price objective on Heron Therapeutics and gave the company a “buy” rating in a report on Tuesday, February 27th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have issued a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $30.08.
Heron Therapeutics (NASDAQ:HRTX) last posted its earnings results on Tuesday, February 27th. The biotechnology company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.29). Heron Therapeutics had a negative net margin of 641.87% and a negative return on equity of 230.70%. The company had revenue of $10.05 million during the quarter, compared to analysts’ expectations of $9.00 million. analysts expect that Heron Therapeutics will post -2.56 earnings per share for the current fiscal year.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of Heron Therapeutics stock in a transaction dated Wednesday, January 10th. The stock was sold at an average price of $20.00, for a total value of $151,680.00. Following the transaction, the vice president now owns 7,584 shares in the company, valued at $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 19.93% of the stock is owned by insiders.
COPYRIGHT VIOLATION NOTICE: This report was published by Sports Perspectives and is the sole property of of Sports Perspectives. If you are viewing this report on another website, it was copied illegally and reposted in violation of US and international trademark & copyright legislation. The original version of this report can be viewed at https://sportsperspectives.com/2018/03/12/heron-therapeutics-hrtx-receives-media-impact-rating-of-0-18.html.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.